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It is not clear whether the association of increased peritoneal protein clearance
(PPCl) with worse survival on peritoneal dialysis (PD) is a consequence of either
local or systemic inflammation or indicative of generalized endothelial dysfunction
associated with comorbidity. To investigate this we determined the relationship of
PPCl to comorbidity, membrane area (equivalent to low molecular weight peritoneal
solute transport rate), local and systemic inflammation and hypoalbuminaemia, and
for each of these with patient survival. 257 incident patients from three GLOBAL Fluid
Study centers were included in this analysis. Clinical profiles were collected at baseline
along with a peritoneal equilibration test, 24-h dialysate protein and paired plasma and
dialysate cytokine measurements. Although peritoneal protein clearance was associated
with increased age and severe comorbidity on univariate analysis, only dialysate IL-6,
peritoneal solute transport rate, plasma albumin and cardiac comorbidities (ischaemic
heart disease and left ventricular dysfunction) were independent explanatory variables
on multivariate analysis. While peritoneal protein clearance and daily peritoneal protein
loss were associated with survival in univariate analysis, on multivariate analysis only
plasma IL-6, age, residual kidney function, comorbidity, and plasma albumin were
independent predictors. Peritoneal protein clearance is primarily a function of peritoneal
membrane area and local membrane inflammation. The association with comorbidity
and survival is predominantly explained by its inverse relationship to hypoalbuminaemia,
especially in diabetics.
Keywords: large pore flux, survival, mortality, hypoalbuminaemia, interleukin-6, peritoneal solute transport rate,
peritoneal membrane, inflammation
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INTRODUCTION
Peritoneal protein clearance (PPCl) has been shown to relate
to comorbidity in several studies (Heaf et al., 2005; Szeto
et al., 2005; Johansson and Haraldsson, 2006; Van Biesen et al.,
2006; Perl et al., 2009; Sánchez-Villanueva et al., 2009; Balafa
et al., 2011) and in many cases to worse survival on peritoneal
dialysis (PD). An attractive explanatory hypothesis would be that
increased PPCl, due to the increased flow of proteins through
the large pore pathway of the peritoneal microvasculature
might reflect systemic endothelial barrier dysfunction and thus
be a biomarker of vascular comorbidity and worse survival
(Figure 1A). However, data from the Netherlands group (Balafa
et al., 2011) demonstrated that while baseline peritoneal albumin
and protein clearances from a 4 h dwell with 3.86% glucose
dialysate were associated with signs of comorbidity there was
no measurable effect on patient survival. Thus the potential
relationships between PPCl, comorbidity and survival remains to
be fully determined, and to date the impact of local peritoneal
inflammation has not been studied.
According to the three pore model, PPCl should be
proportional to peritoneal solute transport rate (PSTR),
given that both large and small pores are located within
peritoneal capillaries. Local peritoneal but not systemic
inflammation is the main predictor of PSTR at the
commencement of dialysis, (Lambie et al., 2013) reflecting
small pore area, but could additionally increase protein
losses by causing a relative increase in large pore area.
The purpose of this analysis was to distinguish between
local versus systemic determinants of PPCl and determine
how these relate to survival using a subgroup of centers in
the Global Fluid Study in which peritoneal protein losses
were measured.
MATERIALS AND METHODS
This was a subgroup analysis of the GLOBAL Fluid study
cohort. A detailed description of the GLOBAL Fluid Study has
been published previously (Lambie et al., 2013). In brief, it is
an international, multi-center, prospective, observational cohort
study where 10 centers from the United Kingdom, Canada,
and South Korea sought to enroll all PD patients starting or
already on PD between 2002 and 2008, with the only exclusion
criterion being lack of informed consent and <18 years of
age. For this analysis, three of the ten centers in the GLOBAL
Fluid study were included, two in the United Kingdom, one in
South Korea, as these centers routinely measured daily dialysate
protein losses. All the incident patients in these three centers in
the GLOBAL Fluid study during 2002 to 2008 were included.
Ethical approval was obtained from the Multi-Center Research
Ethics Committee for Wales covering the United Kingdom, and
the Kyungpook National University Hospital Ethics Committee
for the Korean center. Written informed consent was obtained
from all subjects and they were followed until their death or
the censor date, December, 2011. Two patients using an amino
acid based solution were excluded from the analysis as the
FIGURE 1 | In (A), the link between comorbidity and PPCl is considered to be
a consequence of three possible mechanisms: increased systemic
inflammation, systemic endothelial dysfunction or its association with
albumin – considered as potentially bidirectional because although increased
protein clearance will cause greater protein losses there is also mathematical
coupling. The model proposed in (B) light of these study findings, is that local
not systemic inflammation is the predominant determinant of PPCl and an
independent link with comorbidity, if present, is weak. The link between PPCl
and survival is subordinate to that with plasma albumin, but the bidirectional
association is not fully resolved.
effects of this solution on local inflammatory cytokine production
are unknown.
Prospective Collection of Routine
Clinical Measurements
Samples of dialysate and plasma and extended clinical
phenotype were collected prospectively when patients
were undergoing routine planned clinical assessments of
membrane function within three months of treatment start. The
clinical characteristics, including membrane function, PPCl,
biochemistry profiles, and comorbidity were estimated locally.
Both of the two United Kingdom centers used the original 2.27%
PET for the measurement of PSTR (D/P creatinine) and the
South Korea center calculated the PSTR based on 4 h result from
a 3.86% exchange.
Frontiers in Physiology | www.frontiersin.org 2 February 2019 | Volume 10 | Article 105
fphys-10-00105 February 14, 2019 Time: 19:3 # 3
Yu et al. Peritoneal Protein Leak, Inflammation and Survival
TABLE 1 | Patient demographic and biochemical characteristics, peritoneal membrane function and systemic and dialysate inflammatory cytokines by center.
Center G05 (n = 77) G01 (n = 57) K03 (n = 123)
Age (yr) 56.3 ± 15.3 57.1 ± 14.3 53.3 ± 14.6
Gender (M/F) 47/30 37/20 72/51
BMI (kg/m2) 27.0 ± 5.4 28.2 ± 4.5 23.4 ± 2.9
Comorbidity Grade n (%)
Low 23 (29.9%) 26 (45.6%) 49(40.0%)
Medium 43 (55.8%) 27 (47.4%) 73 (59.2%)
High 11 (14.3%) 4 (7.0%) 1 (0.8%)
DM (yes/no) 27/50 14/43 59/64
Day of PET (day) 42 ± 20 25 ± 19 38 ± 14
Alb (g/L) 35.8 ± 4.2 37.6 ± 4.7 33.4 ± 5.1
Hgb (g/L) 11.9 ± 1.5 11.4 ± 1.4 8.7 ± 2.4
Urine volume (ml) 1203 ± 785 1324 ± 813 1027 ± 620
PSTR 0.77 ± 0.14 0.60 ± 0.12 0.73 ± 0.10
CAPD/APD 59/18 57/0 123/0
Icodextrin (with/without) 20/57 0/57 16/107
Bicarbonate buffered solution (with/without) 2/75 28/29 21/102
PPCl (ml/day) 89.9 ± 33.6 89.7 ± 46.2 95.5 ± 48.3
Dialysate IL-1β AR (pg/min) 0 (0–0) 0 (0–2.12) 0 (0–0.32)
Dialysate TNF-α AR (pg/min) 0 (0–1.78) 3.30 (1.15–8.64) 1.69 (0.28–5.62)
Dialysate IL-6 AR (pg/min) 32.9 (8.8–59.6) 41.7 (23.1–90.6) 73.9 (30.7–135.0)
Dialysate IFN-γ AR (pg/min) 10.5 (0–46.4) 0 (0–15.2) 0 (0–3.3)
Plasma IL-1β (pg/ml) 0.12 (0.06–0.26) 0.01 (0–0.07) 0.05 (0–0.21)
Plasma TNF-α (pg/ml) 7.2 (5.7–8.7) 8.3 (6.7–9.7) 17.6 (15.4–22.0)
Plasma IL-6 (pg/ml) 1.5 (0.7–2.8) 0.8 (0.2–2.3) 2.0 (1.2–3.7)
Plasma IFN-γ (pg/ml) 1.0 (0.4–1.6) 0.7 (0–2.2) 2.2 (1.3–4.0)
BMI, body mass index; PSTR, Peritoneal Solute Transport Rate expressed as dialysate/plasma creatinine at 4 h; PCl, protein clearance; Comorbidity Grade – Davies
Comorbidity grade as defined previously(Davies et al., 2002); AR, appearance rate.
Comorbidity was documented according to the externally
validated Davies comorbidity score (Davies et al., 2002). Briefly,
7 comorbid domains were considered, including non-cutaneous
TABLE 2A | Univariate associations between PPCl, patient and membrane
characteristics, plasma and dialysate inflammatory cytokines.
Correlation Coefficienta
Age 0.15
BMI 0.05
Serum albumin −0.47
PSTR 0.44
24 h urine volume −0.02
Dialysate IL-1β AR 0.04
Dialysate TNF-α AR 0.14
Dialysate IL-6 AR 0.20
Dialysate IFN-γ AR 0.04
Plasma IL-1β 0.02
Plasma TNF-α 0.06
Plasma IL-6 0.13
Plasma IFN-γ −0.01
a, Pearson correlation coefficient for normal distributed variables and Spearman
correlation coefficient for non-normal distributed variables. BMI, body mass index;
PP, pulse pressure; PSTR, Peritoneal Solute Transport Rate, (4 h dialysate/plasma
creatinine); Ccr, creatinine clearance; IL, interleukin; TNF, tumor necrosis factor; INF,
interferon; AR, appearance rate.
malignancy, ischemic heart disease (IHD), peripheral vascular
disease (PVD) (including cerebrovascular and renovascular
disease), left ventricular dysfunction (LVD), diabetes mellitus
(DM), systemic collagen vascular disease, and ‘other’ (any
other condition known to reduce life expectancy in the
general population). The comorbidity score for each patient
was defined as the number of these domains affected. The
comorbidity grade was then derived from the comorbidity score.
Grade 0 (low risk) was a zero score, grade 1 (medium risk)
was a score of 1–2, and grade 2 (high risk) a cumulative
score of ≥3.
The peritoneal dialysate protein loss was measured from
the collection of 24-h peritoneal dialysate eﬄuent. A validated
correction factor was used to calculate PPCl: 24 h dialysate
protein loss/(serum albumin/0.4783), (Haraldsson, 1995) and
expressed as mL/day.
Sample Analysis
Dialysate and plasma samples were stored locally at
−80◦C, and were sent to a central laboratory for
measurements of IL-1β, TNF-α, IL-6 and INF-γ by
electrochemiluminescence immune assay using the commercially
available Pro-Inflammatory I 4-plex (Meso-Scale Discovery,
Gaithersburg, MD, United States). For correlations and
comparisons, dialysate appearance rate (AR) of cytokines
was calculated from the dialysate concentration divided
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TABLE 2B | Univariate associations between PPCl and patient characteristics.
PPCl, ml/day mean ± SD
Gender Male 96.3 ± 45.5
Female 87.4 ± 41.1
Comorbidity grade Low 79.4 ± 37.0
Medium 99.6 ± 43.1
High 109.7 ± 67.0
PD modality CAPD 92.4 ± 44.6
APD 94.5 ± 33.9
Icodextrin Without 90.2 ± 35.5
With 92.9 ± 45.1
Biocompatible solution Without 88.1 ± 38.5
With 93.6 ± 45.1
DM Without 85.8 ± 39.59
With 103.1 ± 48.12
IHD Without 88.46 ± 39.93
With 112.24 ± 55.72
LVD Without 89.98 ± 40.34
With 118.53 ± 66.01
Malignancy Without 92.15 ± 43.8
With 106.14 ± 46.83
PVD Without 91.38 ± 43.86
With 101.61 ± 43.43
Collagen disease Without 92.69 ± 43.86
With 78.86 ± 48.93
DM, Diabetes Mellitus; IHD, Ischaemic Heart Disease; LVD, Left Ventricular
Dysfunction; PVD, Peripheral Vasculare Disease.
by dwell time. The median intra-assay coefficient of
variation was 8.0.
Statistical Analysis
Continuous data were expressed as mean values ± SD for
normally distributed variables; otherwise median (± inter-
quartile range) was used unless they could be log10 transformed.
One-way ANOVA or Student’s t-test were used to examine
differences in normally distributed continuous data or baseline
categorical variables, while Mann-Whitney or Kruskal-Wallis
tests were used for non-parametric variables. The relationship
between PPCl and continuous variables was examined by Pearson
correlation coefficient.
Mixed linear modeling was used to identify the determinants
of PPCl with a random intercept for center to account for
the observed center effects. Kaplan-Meier plots with log rank
tests and Cox regression with robust standard errors were
used for survival analysis. Collinearity was assessed using a
variation inflation factor of >5 as a pree-specified cutoff to
indicate a problem.
Significance was pre-specified for p-values <0.05 and 95%
confidence intervals not crossing the value for no effect. All
statistical analyses were performed using SPSS 20 (SPSS Inc.,
Chicago Ill., United States) apart from the mixed linear model,
which was performed by MLwin software (Version 2.22, Center
for multilevel modeling University of Bristol).
RESULTS
Patient and Membrane Characteristics
A total of 257 patients in the three centers were included in
the study. Table 1 displays the main baseline characteristics.
There were significant differences between centers in a variety
of variables, including BMI, comorbidity, PSTR, residual renal
function and biochemical characteristics and all the plasma and
dialysate cytokines levels. The dialysis regime was also different
among centers.
Univariate Correlation to PPCl
The univariate correlations between PPCl, patient and membrane
characteristics, as well as dialysate and plasma inflammatory
cytokines are presented in Table 2. PPCl was positively related to
age and PSTR (Figure 2A). A strong negative correlation was seen
between PPCl and serum albumin, which is in part a function
of mathematical coupling. No significant difference in PPCl was
found according to icodextrin use, biocompatible solution use or
modality (CAPD versus APD).
Both dialysate IL-6 appearance rate (AR) and less strongly
plasma IL-6 were positively correlated to PPCl (Figure 2B and
Table 2) Dialysate but not plasma TNF-α were related to PPCl.
PPCl was associated both with the overall severity of comorbidity,
(Figure 2C) and with specific comorbidities, namely IHD, DM,
and LVD (Table 2B).
Multivariate Model for PPCl
To account for clustering by center, a random intercept term was
used for center. Gender, age, comorbidity grade, Log10 dialysate
IL-6 AR, Log10 plasma IL-6, and PSTR were included in the
multivariate model.
With PPCl as the dependent variable, dialysate IL-6 AR,
plasma albumin and PSTR were the independent explanatory
variables (Table 3). Further models substituting specific
comorbid domains instead of the overall comorbidity grade
showed that IHD and LV dysfunction predicted higher PPCl,
but not DM, PVD or other comorbidities (Supplementary
Tables 1, 2). A sensitivity analysis using daily peritoneal protein
loss as an alternative measure to peritoneal protein clearance
showed a similar pattern but no correlation to plasma albumin,
(Supplementary Table 4). Tests for collinearity demonstrated no
significant effect, with the highest variance inflation factor of 1.49
for albumin. Variables included in models were selected a priori,
i.e., on the basis of previous reported associations or biological
plausibility, with no statistical criteria used for selection.
Survival Analysis
There were 115 deaths in the 257 patients during a median follow
up of 37 months. In the Kaplan-Meier plot, the survival rate was
compared between patients with PPCl split by the median value
of the whole group. Higher PPCl was shown to be related to worse
overall outcome and this was also true for daily peritoneal protein
loss (Figure 3).
Using Cox regression, in the basic model which also
included gender, renal Kt/V, local and systemic inflammation,
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FIGURE 2 | Univariable associations of peritoneal protein clearance. (A) PPCl
and PSTR (D/P creatinine), (B) PPCl and Dialysate IL-6 AR (pg/min),
(r-correlation coefficient of univariable assosication), and (C) PPCl and
comorbidity grade.
the independent predictors of survival were age, renal Kt/V,
systemic IL-6, PSTR, and comorbidity. On adding PPCl
into the model, the predictive value of PSTR was displaced
by a significant association with PPCl. By further adding
plasma albumin into the model, the significant prediction
TABLE 3 | Multivariable model for PPCla.
β 95% CI P-value
PSTR (for each 0.1 increase
D/P creatinine)
11.88 7.83–15.93 <0.001
Dialysate IL6 AR (for each 10
fold increase)
8.70 0.82–16.59 0.03
Plasma IL6 (for each 10 fold
increase)
5.55 −10.05–21.15 0.49
Albumin (for each 1g/L
increase)
−2.70 −3.76–1.63 <0.001
Age (year) 0.04 −0.28–0.35 0.82
Male gender −0.45 −9.46–8.56 0.92
Comorbidity Grade 1
(compared with Grade 0)
6.72 −3.05–16.49 0.44
Comorbidity Grade 2
(compared with Grade 0)
10.01 −9.81–29.83
a, mixed linear model with random intercept for center. PPCl, peritoneal protein
clearance; PSTR, peritoneal solute transport rate; AR, appearance rate; IL-6,
interleukin-6.
of mortality by PPCl was displaced, with age, renal Kt/V,
plasma IL-6, comorbidity grade, and plasma albumin the
independent predictors for survival (Table 4). Application of
the likelihood ratio test confirmed that addition of PPCl
to the models confirmed that it was only a significant
predictor until plasma albumin, with which it is correlated
was added to the model, resulting in an overall better
prediction. The lack of association of PPCl with survival
was not altered by substituting specific comorbidities into the
model (see Supplementary Table 3). When daily protein loss
was substituted for PPCl in the third model this was not a
significant predictor (Hazard Ratio 1.06/g/day, (95%CI 0.96–
1.17). A sensitivity analysis including hemoglobin as a covariate
made no substantive difference.
DISCUSSION
The purpose of this sub-analysis of the GLOBAL Fluid study
was to determine whether PPCl is a consequence of local
peritoneal membrane inflammation or a reflection of vascular
injury associated with systemic inflammation and comorbidity
and, in turn understand how these associate with subsequent
patient survival. This is the first time to our knowledge that both
local and systemic inflammation, PSTR, PPCl, and comorbid
conditions have all been measured at the same time. We
demonstrated that PPCl is a function of local inflammation
(as reflected by the product of effective membrane area
and local dialysate IL-6 appearance rate) and not systemic
inflammation in patients commencing PD. The association
of comorbidity with PPCl is predominantly explained by the
inverse correlation to plasma albumin. This is for several
reasons including the reverse acute phase response associated
with systemic inflammation, which is in part causal, as a
greater protein loss will cause the albumin to drop, but
predominantly due to mathematical coupling. The calculation of
PPCl has albumin as its denominator which will be depressed
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FIGURE 3 | (A) Kaplan-Meier curve for peritoneal protein clearance (PCl) (log rank test) and (B) Kaplan-Meier curve for daily peritoneal protein loss (log rank test).
in the presence of systemic inflammation. Thus PPCl is not
an independent predictor of survival in this analysis which
takes both systemic and local inflammation into account,
suggesting that the previously reported associations were not
due to an association with systemic inflammation or endothelial
barrier dysfunction, as demonstrated in the revised causal
diagram, Figure 1B.
Several studies have shown that membrane inflammation is
associated with high PSTR, primarily a measure of the effective
membrane area in incident patients (van Esch et al., 2004; Hwang
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TABLE 4 | Cox regression models of patient survival stratified by center – with PPCl and plasma albumin as additional covariates.
Base Model Base Model + PPCl Base Model + PPCl + Alb
HR 95%CI P-value HR 95%CI P-value HR 95%CI P-value
Age (per year) 1.075 1.05–1.1 <0.01 1.076 1.05–1.1 <0.01 1.077 1.05–1.1 <0.01
Gender (Female) 1.154 0.75–1.77 0.51 1.179 0.76–1.83 0.47 1.192 0.77–1.85 0.43
PSTR 9.912 1.8–54.44 <0.01 3.393 0.42–27.26 0.25 2.681 0.36–20 0.34
Plasma IL-6 (per 10 fold increase) 2.397 1.18–4.89 <0.05 2.239 1.06–4.71 <0.05 2.201 1.08–4.47 <0.05
Comorbidity grade 1 2.271 1.4–3.69 <0.01 2.063 1.26–3.38 <0.01 1.827 1.09–3.05 <0.05
Comorbidity grade 2 7.787 3.36–18.04 <0.01 7.198 3.22–16.1 <0.01 4.933 2.07–11.78 <0.01
Peritoneal IL-6 AR (per log order) 1.098 0.77–1.56 0.6 1.047 0.72–1.53 0.81 1.040 0.7–1.54 0.84
Renal Kt/V (per unit) 0.614 0.42–0.9 <0.05 0.634 0.43–0.93 <0.05 0.658 0.46–0.95 <0.05
PfopPCl (per ml/min) 1.005 1–1.01 <0.05 1.002 1–1.01 0.5
Plasma Albumin (per g/l) 0.924 0.87–0.98 <0.01
PPCl, peritoneal protein clearance; PSTR, peritoneal solute transport rate; AR, appearance rate; IL-6, interleukin-6; HR, hazard ratio, CI, confident interval.
et al., 2009; Lambie et al., 2013). However, until now it has
not been clear how this relates to the variability in large pore
flux. It is well known that the large pore flux (and thus PPCl)
increases dramatically during peritonitis, i.e., in the presence of
severe inflammation that includes an influx of neutrophils, but
this has been less clear in the context of a stable, non-infected
peritoneal cavity. A study in 40 prevalent CAPD patients found
that the dialysate appearance of IL-6 correlated with albumin
and IgG clearances, which was also related to PSTR at the same
time (Pecoits-Filho et al., 2002). It was not clear from this
study, however, whether the inflammation associated increase
of PPCl was fully explained by an increase in membrane area.
Our results indicate that local IL-6 production, increases PPCl
not just via increased effective area (PSTR), but also through
an increase in the density of large pores leading to a more
leaky membrane.
Although the hypothesis that PPCl reflects generalized
endothelial dysfunction is attractive, our findings from the
multivariate analysis did not support this assumption. We
demonstrated that comorbidity was not an independent predictor
of PPCl (after controlling for local and systemic inflammation,
PSTR and plasma albumin). This is consistent with previous
findings in a longitudinal single center cohort study, (Yu
et al., 2014) where no significant correlation between PPCl and
comorbidity was observed, albeit in a highly selected cohort
(restricted to patients on PD for more than 4 years). This
longitudinal study also found that PPCl decreases with time
for a given membrane area, despite the fact that comorbidity
tends to accumulate with time on PD, suggesting that progressive
membrane fibrosis is occuring (Yu et al., 2014). Furthermore,
detailed analysis of the transcapillary escape rate of albumin, a
measure of systemic endothelial barrier dysfunction, found that
this was highly abnormal in PD patients, in keeping with an
impaired glycocalyx in dialysis patients, (Vlahu et al., 2012) but
found no relationship to either systemic inflammation or PPCl.
Given that this was a study of prevalent patients who may have
acquired membrane fibrosis its interpretation requires caution,
but it is nevertheless further evidence that systemic impairment
of endothelial barrier function is not a major determinant of PPCl
(Yu et al., 2012). PPCl is therefore predominantly a function of
peritoneal membrane inflammation and membrane surface area
rather than a reflection of systemic endothelial injury.
In addition to the analyses testing our primary hypothesis,
we undertook exploratory analyses of the association between
different comorbidities and PPCl. Whereas DM was not
independently associated with PPCl, this was the case for IHD
and LV dysfunction (Supplementary Table 2). The explanation
for this is not certain, but we did observe that patients with IHD
had greater systemic inflammation [plasma IL-6 IHD 2.40 pg/ml
(1.30–4.35) vs. DM 1.86 pg/ml (1.03–3.02)], whereas those with
DM had a more marked reduction in plasma albumin. This agrees
with the findings of the previously cited single center study,
(Yu et al., 2012) incorporating a much wider biomarker profile,
which found systemic inflammation was more pronounced in
IHD whereas platelet activation and systemic albumin leak (not
peritoneal) was more significant in DM, suggesting differential
effects according to type of comorbidity on endothelial function.
Other factors to be taken into account include the different
kinetics of peritoneal protein loss as compared to systemic
protein leak on plasma albumin (which can be recycled) and
other factors that could theoretically increase peritoneal protein
losses such as transcapillary hydrostatic pressure. One of the
limitations of the present study is that it may not have been large
enough to demonstrate different effects by comorbidity on PPCl
and survival.
There were a number of other limitations of our study.
Firstly, athough a validated correction factor was used to estimate
total protein from serum albumin a direct measurement of
total plasma protein may have given different results. It is
possible that in extreme systemic inflammation, total serum
protein may be underestimated and PPCl overestimated because
while albumin is a negative acute-phase protein, other proteins
increase in inflammation. Thus, the association between systemic
inflammation and PPCl may have been amplified, as it may
have been in previous studies. However, this does not alter the
conclusions of this study, namely that PPCl is more associated
with local than systemic inflammation. Secondly, albumin, the
predominant plasma and dialysate protein, is able to pass through
small pores (predominantly by convection) as well as large pores
(Lindholm et al., 1987). Ideally, a series of proteins at different
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molecular weights should be measured to precisely dissect out
the contribution of the different pore sizes, a procedure that is
logistically challenging for a large prospective epidemiological
study such as this. Thirdly, proteinuria, another route of protein
loss that can affect plasma albumin levels in PD patients, (Gama-
Axelsson et al., 2012) would be measured as this may differ by
comorbidity. Unfortunately, these measures were not available
in this study. Fourthly, a larger study may have been able to
show independent effects of more of the covariates on survival;
for example a recent study (Mehrotra et al., 2015) of more than
10,000 new patients found a significant association between high
solute transport and survival that was not observed here.
Finally, as for all observational studies, we cannot prove
causality in the association of peritoneal inflammation with
PPCl, although it fits a lot of the Bradford-Hill criteria for
causality. Our survival analysis is primarily disproving a causal
association suggested by previous studies so this caveat is less
relevant. An interventional trial of an agent that turns off
intraperitoneal inflammation would be required to investigate
causality. The strengths of the present study include the multi-
center multinational nature of the study whilst still allowing
for clustering by center in the analysis, the large number of
patients studied, length of follow up and adjustment for multiple
confounding covariates.
Summary
In conclusion, we have shown that PPCl is predominantly
determined by peritoneal membrane area and local
inflammation. The predictive value of PPCl on survival is mainly
through its coupling to hypoalbuminaemia rather than a direct
reflection of endothelial injury. PPCl is not a good marker for
systemic endothelial function but a reflection of local peritoneal
membrane inflammation.
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